India Glycols Ltd

- The company prepaid around INR804 crores in the recent quarter, partly funded by INR467 crores through an equity issue in November 2025 and the rest from cash flow. - There is a liability of INR268 crores due in FY '26-'27, planned to be paid off. - The company is in the process of reducing debt further and targeting prepayments based on cash flow but has not committed to a fixed repayment amount. - Plans for raising capital through debt or equity beyond this are not explicitly mentioned, indicating no immediate new fundraising is announced. - Management aims to achieve a debt-free status for the Chemical business by FY '28-'29 using proceeds from partial equity sale of the JV. - Interest costs are expected to remain at around INR25 crores per quarter, suggesting stable financing costs without significant new borrowings.

- INR 830 crores capital expenditure done in the year, with about INR 400 crores invested in two main grain distilleries located at Gorakhpur and Kashipur. - Additional smaller capex projects completed besides the distilleries. - Future debt repayments planned: INR 268 crores liability for FY27, with ongoing efforts to reduce debt further based on cash flow. - Scheme of arrangement for demerger expected to have NCLT hearing by May 21, 2026, with anticipated order in early June, paving way for restructuring and potential strategic moves thereafter. - Continued investments in Ennature Biopharma segment focusing on manufacturing capabilities and customer acquisition for growth and profitability enhancement. - Ongoing strategic shift towards premiumization in Potable Spirit segment with focus on launching more premium brands for future revenue increase.

- Chemicals segment expected to see good growth driven by performance chemicals and new products like bio-based amines and dibasic esters. - Potable Spirits revenue growing, driven by premiumization in IMFL and new product launches (e.g., Bunty Vodka 122% growth, Bunty Jamun). - Bio-Fuels segment shows strong growth with 40.9% increase in FY26 revenue; potential for further growth if ethanol blending targets rise beyond 20% and flexi-fuel vehicles expand. - Ennature Biopharma targeting volume growth via new customer additions, clinical-backed nutraceutical launches, and planned entry into the U.S. market. - Capex focused on expanding two grain distilleries (Gorakhpur and Kashipur) supports future production capacity. - Ongoing efforts to improve Chemicals business quality and expand product portfolio expected to sustain growth. - Premiumization strategy in Potable Spirits likely to increase revenue share from IMFL and improve margins. - Bio-Fuels expected to benefit from government policy support and stable input costs, supporting volume and profit growth.

- Chemicals business: Cautiously optimistic with expected improved profitability and top-line growth; performance chemicals segment growing strongly with potential for doubling revenue this year and sustained momentum. - Bio-Fuels: Strong growth driven by 20% ethanol blending policy, with possible future increases beyond 20%; profitability expected to remain healthy due to stable grain prices and policy support. - Ennature Biopharma: Profitability under pressure but expected to improve due to diversification into branded nutraceuticals, clinical studies, and expansion into US markets. - Potable Spirits: Margins maintained around 22%; growth driven by premiumization and new product launches in key regions. - Overall EBITDA margin improved to 15.5% in FY26, with 24.5% EBITDA growth and 26.8% PAT growth, indicating strong earnings momentum going forward. - Debt reduction and cost control measures leading to better interest coverage and financial health, supporting future profit growth.

The transcript provided from India Glycols Limited's Q4 & FY26 earnings call does not specifically mention details about the current or expected order book or pending orders. Key focuses instead were on: - Capital expenditure mainly in two grain distilleries (Gorakhpur and Kashipur). - Debt repayment and reduction plans. - Business segment performances including Chemicals, Potable Spirits, Bio-Fuels, and Ennature Biopharma. - Shifts towards premiumization in the Potable Spirits segment. - Updates on JV performance and monetization timelines. - Impact of plant shutdowns on production and sales. Therefore, there is no explicit information available about the current or expected order book or pending orders in this document.